Entity information:

NOTE 11—Income Taxes

Components of income tax expense

The U.S. and foreign components of the Company’s income before provision for income taxes consisted of the following (in thousands):

 

     Fiscal Years Ended  
     February 28,
2017
     February 29,
2016
     February 28,
2015
 

U.S.

   $ 187,316      $ 155,550      $ 167,388  

Foreign

     132,864        119,315        88,110  
  

 

 

    

 

 

    

 

 

 

Income before provision for income taxes

   $ 320,180      $ 274,865      $ 255,498  
  

 

 

    

 

 

    

 

 

 

The components of the Company’s provision for income taxes consisted of the following (in thousands):

 

     Fiscal Years Ended  
     February 28,
2017
    February 29,
2016
    February 28,
2015
 

Current:

      

Foreign

   $ 35,791     $ 39,168     $ 26,325  

Federal

     16,857       44,872       15,252  

State

     1,502       5,133       4,090  
  

 

 

   

 

 

   

 

 

 

Current tax expense

   $ 54,150     $ 89,173     $ 45,667  

Deferred:

      

Foreign

     (4,854     (5,170     (8,188

Federal

     17,712       (6,142     36,197  

State

     (531     (2,361     1,621  
  

 

 

   

 

 

   

 

 

 

Deferred tax expense (benefit)

   $ 12,327     $ (13,673   $ 29,630  
  

 

 

   

 

 

   

 

 

 

Net provision for income taxes

   $ 66,477     $ 75,500     $ 75,297  
  

 

 

   

 

 

   

 

 

 

 

Statutory Rate Reconciliation

Taxes computed at the statutory federal income tax rates are reconciled to the provision for income taxes as follows (in thousands):

 

     Fiscal Years Ended  
     February 28, 2017     February 29, 2016     February 28, 2015  

Provision at federal statutory rate

   $ 112,063        35.0   $ 96,203        35.0   $ 89,424        35.0

State tax, net of federal tax benefit

     520        0.2     601        0.2     4,042        1.6

Foreign rate differential (1)

     (11,795      (3.7 )%      (8,232      (3.0 )%      (13,983      (5.5 )% 

Foreign dividend

     —          —       —          —       8,720        3.4

Nondeductible items

     3,077        1.0     3,426        1.2     3,339        1.3

Share-based compensation (2)

     (12,749      (4.0 )%      149        0.1     105        —  

Research tax credit

     (9,532      (3.0 )%      (5,105      (1.9 )%      (5,329      (2.1 )% 

Foreign tax credit

     (8,930      (2.8 )%      (10,267      (3.7 )%      (11,755      (4.6 )% 

Domestic production activities deduction

     (4,601      (1.4 )%      (5,033      (1.8 )%      (4,433      (1.7 )% 

Other

     (1,576      (0.5 )%      3,758        1.4     5,167        2.1
  

 

 

    

 

 

   

 

 

    

 

 

   

 

 

    

 

 

 

Provision for income taxes

   $ 66,477        20.8   $ 75,500        27.5   $ 75,297        29.5
  

 

 

    

 

 

   

 

 

    

 

 

   

 

 

    

 

 

 

 

(1) Foreign rate differential includes a reduction of $1.5 million related to a tax holiday in Israel. The tax holiday provides for a reduced tax rate on income attributable to research and development activities and is scheduled to terminate as of the fiscal year ending February 29, 2020. The financial impact from the tax holiday for the fiscal year ended February 28, 2017 resulted in an increase to the Company’s diluted earnings per share of approximately $0.01.
(2) Share-based compensation in the fiscal year ended February 28, 2017 includes $15.8 million net windfall tax benefits from share-based payments resulting from the Company’s early adoption of ASU 2016-09. See NOTE 2—Summary of Significant Accounting Policies for additional discussion regarding the adoption of ASU 2016-09. This windfall is offset by certain stock-based compensation for which the Company receives no tax benefit.

Deferred taxes

Significant components of the Company’s deferred tax assets and liabilities consisted of the following (in thousands):

 

     February 28,
2017
    February 29,
2016
 

Deferred tax assets:

  

Foreign net operating loss carryforwards

   $ 4,218     $ 6,679  

Domestic net operating loss carryforwards

     5,696       13,202  

Domestic credit carryforwards

     9,864       7,849  

Share-based compensation

     51,016       44,276  

Deferred revenue

     97,258       83,901  

Foreign deferred royalty expenses

     2,505       9,896  

Convertible notes

     11,377       15,182  

Other

     17,077       12,313  
  

 

 

   

 

 

 

Total deferred tax assets

     199,011       193,298  

Valuation allowance for deferred tax assets

     (5,621     (3,291
  

 

 

   

 

 

 

Total deferred tax assets, net of valuation allowance

     193,390       190,007  
  

 

 

   

 

 

 

Deferred tax liabilities:

  

Goodwill

     10,757        9,450  

Property and equipment

     25,163        22,669  

Identifiable intangible assets

     21,101        21,416  

Compensation accruals

     30,128        21,415  

Other

     4,347        3,770  
  

 

 

    

 

 

 

Total deferred tax liabilities

     91,496        78,720  
  

 

 

    

 

 

 

Net deferred tax asset (1)

   $ 101,894      $ 111,287  
  

 

 

    

 

 

 

 

(1) Net deferred tax asset is reported on the Company’s Consolidated Balance Sheets as Deferred tax assets, net and included in Other long-term obligations.

The Company maintains a valuation allowance against its deferred tax assets with respect to certain foreign and state NOL and credit carryforwards that the Company does not believe will ultimately be realized. For the fiscal year ended February 28, 2017, the valuation allowance increased $2.3 million primarily as a result of foreign NOL and credit carryforwards acquired through recent acquisitions.

As of February 28, 2017, the Company had U.S. federal NOL carryforwards of $9.2 million, foreign NOL carryforwards of $22.9 million and U.S. state NOL carryforwards of $72.3 million. The NOL carryforwards expire in varying amounts beginning in the fiscal year ending February 28, 2018. As of February 28, 2017, the Company had U.S. federal research tax credit carryforwards of $0.8 million, state research tax credit carryforwards of $18.1 million and foreign research tax credit carryforwards of $1.2 million, which expire in varying amounts beginning in the fiscal year ending February 28, 2018.

As of February 28, 2017, cumulative undistributed earnings of non-U.S. subsidiaries totaled $677.4 million. Determination of the deferred tax liability on these earnings reinvested indefinitely outside the U.S. is not practicable because of available foreign tax credits, continually changing variables and other factors. It is the Company’s policy to invest the earnings of foreign subsidiaries indefinitely outside the U.S. From time to time, however, the Company may remit a portion of these earnings to the extent it is economically prudent. The Company has provided U.S. income taxes on the earnings of certain foreign subsidiaries that are not considered as permanently reinvested outside the U.S. The U.S. income tax on such earnings has been offset by U.S. foreign tax credits. The Company has also provided U.S. income taxes on the earnings of certain foreign subsidiaries that are permanently reinvested outside the U.S. but are deemed distributed for U.S. federal income tax purposes. The U.S. income tax on such earnings is reduced or offset by available U.S. foreign tax credits.

Unrecognized tax benefits

The following table reconciles unrecognized tax benefits (in thousands):

 

     February 28,
2017
    February 29,
2016
    February 28,
2015
 

Balance at beginning of year

   $ 74,886     $ 60,343     $ 57,054  

Additions based on tax positions related to prior years

     2,142       13,486       514  

Additions based on tax positions related to the current year

     4,893       3,494       3,374  

(Reductions) additions related to changes in facts and circumstances

     (2,271     256       (229

Reductions related to lapse of the statute of limitations

     (2,748     (1,581     (370

Reductions related to settlements with tax authorities

     —         (1,112     —    
  

 

 

   

 

 

   

 

 

 

Balance at end of year

   $ 76,902     $ 74,886     $ 60,343  
  

 

 

   

 

 

   

 

 

 

 

The Company’s unrecognized tax benefits as of February 28, 2017 and February 29, 2016, which, if recognized, would affect the Company’s effective tax rate were $69.1 million and $59.1 million, respectively.

It is the Company’s policy to recognize interest and penalties related to uncertain tax positions as income tax expense. Uncertain tax position interest and penalties recognized in the Consolidated Statements of Operations totaled $2.5 million, $1.5 million and $2.7 million for the fiscal years ended February 28, 2017, February 29, 2016 and February 28, 2015, respectively. Uncertain tax position accrued interest and accrued penalties recognized in the Consolidated Balance Sheets totaled $13.2 million and $10.7 million as of February 28, 2017 and February 29, 2016, respectively.

As of February 28, 2017, it is reasonably possible that total unrecognized tax benefits may be reduced by up to $7.6 million within the next 12 months as a result of statutes of limitations expirations in various tax jurisdictions, all of which would affect the Company’s effective tax rate.

The Company is subject to taxation in the U.S. and various other state and foreign jurisdictions. The material jurisdictions in which the Company is subject to potential examination include India, Ireland and the U.S., where the Company is no longer subject to examination prior to fiscal years ended February 28, 2006, February 29, 2012 and February 29, 2000, respectively. The Company is currently under examination in France, India and the United Kingdom. The Company believes it has adequately provided for any reasonably foreseeable outcomes related to tax audits.